Helixgate

Our Experts

Contributors & Intelligence Network

Helixgate Biotech Review brings together leading voices across biotechnology, advanced research, computational sciences, and capital markets.
Our contributors include scientists, founders, investors, and strategic operators shaping the future of life sciences.

Dr. Elena Vasquez

Senior Intelligence Analyst

AI & Drug Discovery

Dr. Vasquez is a computational biologist with over 15 years of experience in AI-driven drug discovery. She previously led machine learning initiatives at a major pharmaceutical company.

Prof. James Chen

Contributing Editor

Synthetic Biology

Prof. Chen is a leading researcher in metabolic engineering and synthetic biology at MIT. His work focuses on engineering microbial systems for industrial biotechnology.

Dr. Sarah Okafor

Contributing Analyst

Gene Therapy & Cell Therapy

Dr. Okafor specializes in gene therapy vector development and has contributed to multiple clinical-stage gene therapy programs at leading biotech companies.

Dr. Michael Torres

Contributing Analyst

Diagnostics & Precision Medicine

Dr. Torres is a molecular diagnostics expert focused on liquid biopsy technologies and precision oncology. He advises several diagnostic startups.

Dr. Priya Sharma

Contributing Editor

Regulatory & Policy

Dr. Sharma specializes in biotechnology regulatory affairs and science policy, with experience at the FDA and major regulatory consulting firms.

Mason Strathmore

Founder & Managing Director

Join Us

Call for Contributors

Researchers, founders, analysts, and technologists interested in contributing perspectives on biotechnology innovation are invited to contact the editorial team.

Mason Strathmore

Founder & Managing Director
Helixgate Biotech Review | Shadowgate Visionary Innovations

Mason Strathmore is the Founder of Helixgate Biotech Review and a strategic operator at the intersection of biotechnology, advanced computational systems, and capital infrastructure.

His work focuses on bridging scientific innovation with scalable capital deployment, with an emphasis on accelerating drug discovery timelines, research efficiency, and infrastructure development across the life sciences sector.

Through Helixgate, Mason is building a high-tech intelligence platform designed to connect leading biotech organizations, research institutions, and investment groups with next-generation operating systems and strategic insights.

Founding Contributors (Invited Network)

Helixgate is actively onboarding a select group of founding contributors across key domains in biotechnology and advanced systems.

Senior Scientist — Immunotherapy & Oncology

Director of Drug Discovery — Top 10 Pharma

AI/ML Research Lead — Computational Biology

Venture Partner — Life Sciences Investment Fund

Clinical Research Strategist — Phase II/III Trials

Biotech Infrastructure Developer — Lab & Campus

Contributor Domains

Our intelligence network is categorized into four critical pillars of the life sciences ecosystem.

Scientific Contributors

Researchers, PhDs, and lab directors driving the next wave of biotech innovation.

Focus: Discoveries, Methodologies

Computational & Systems

AI, ML, and Data Modeling experts building the digital infrastructure.

Focus: Acceleration, Simulation

Capital & Investment

PE, VC, and Family Offices funding the future of scalable biotechnology.

Focus: Deal Flow, Scaling

Infrastructure & Dev

Specialists in life science real estate and advanced lab build-outs.

Focus: Physical Ecosystems

Join the Helixgate Intelligence Network

We selectively collaborate with experts across biotechnology, computational systems, and capital markets. If you are actively shaping the future of life sciences and are interested in contributing insights, research, or strategic perspectives, we welcome qualified inquiries.

All contributions are reviewed for scientific accuracy, strategic relevance, and industry impact. Helixgate Biotech Review maintains a high standard of clarity, credibility, and forward-thinking analysis across all published materials.